Developmental patterns of DR6 in normal human hippocampus and in down syndrome

Journal of Neurodevelopmental Disorders

Volumn 5, Issue 1, 2013, Pages 1-14

  Iyer, Anand ^a   van Scheppingen, Jackelien ^a   Anink, Jasper ^a   Milenkovic, Ivan ^b   Kovács, Gabor G ^b   Aronica, Eleonora ^a,c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; APP; Death receptor 6; Development; Down syndrome; Hippocampus; Neurodegeneration

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 6; DEATH RECEPTOR; DEATH RECEPTOR 6; N TERMINAL BETA AMYLOID PRECURSOR PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BIRTH; BRAIN; BRAIN DEVELOPMENT; BRAIN HOMOGENATE; CHILD; CONTROLLED STUDY; DENTATE GYRUS; DEVELOPMENTAL STAGE; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEURITE; NEUROPATHOLOGY; POSTNATAL DEVELOPMENT; PRENATAL DEVELOPMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; SIGNAL TRANSDUCTION; STRATUM LACUNOSUM MOLECULARE; STRATUM ORIENS; STRATUM PYRAMIDALE; STRATUM RADIATUM; TEMPORAL CORTEX; WESTERN BLOTTING; WHITE MATTER;

EID: 84878793090     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/1866-1955-5-10     Document Type: Article

References (47)

1. Wajant H: Death receptors. Essays Biochem 2003, 39:53-71
2. Rossi D, Gaidano G: Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003, 88:212-218
3. Bhardwaj A, Aggarwal BB: Receptor-mediated choreography of life and death. J Clin Immunol 2003, 23:317-332.
4. Sheikh MS, Huang Y: Death receptors as targets of cancer therapeutics. Curr Cancer Drug Tar 2004, 4:97-104.
5. Mi S, Lee X, Hu Y, Ji B, Shao Z, Yang W, Huang G, Walus L, Rhodes K, Gong BJ, Miller RH, Pepinsky RB: Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med 2011, 17:816-821
6. Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC, Weimer RM, Carano RA, van Bruggen N, Watts RJ: Death receptors DR6 and TROY regulate brain vascular development. Dev Cell 2012,22:403-417
7. Benschop R, Wei T, Na S: Tumor necrosis factor receptor superfamily member 21: TNFR-related death receptor 6, DR6. Adv Exp Med Biol 2009, 647:186-194.
8. Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, Vincenz C, Aggarwal BB, Ni J, Dixit VM: Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998,431:351-356
9. Zeng L, Li T, Xu DC, Liu J, Mao G, Cui MZ, Fu X, Xu X: Death receptor 6 induces apoptosis not through Type I or Type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein. J Biol Chem 2012, 287:29125-29133.
10. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
11. Kim D, Tsai LH: Bridging physiology and pathology in AD. Cell 2009, 137:997-1000.
12. Vohra BP, Sasaki Y, Miller BR, Chang J, DiAntonio A, Milbrandt J: Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway. J Neurosci 2010, 30:13729-13738
13. Jefferson T, Čaušević M, auf dem Keller U, Schilling O, Isbert S, Geyer R, Maier W, Tschickardt S, Jumpertz T, Weggen S, Bond JS, Overall CM, Pietrzik CU, Becker-Pauly C: Metalloprotease meprin B generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem 2011, 286:27741-27750.
14. Guo Q, Li H, Gaddam SS, Justice NJ, Robertson CS, Zheng H: Amyloid precursor protein revisited: neuron-specific expression and highly stable nature of soluble derivatives. J Biol Chem 2012, 287:2437-2445
15. Ponomarev SY, Audie J: Computational prediction and analysis of the DR6-NAPP interaction. Proteins 2011, 79:1376-1395
16. Kuester M, Kemmerzehl S, Dahms SO, Roeser D, Than ME: The crystal structure of death receptor 6 (DR6): a potential receptor of the amyloid precursor protein (APP). J Mol Biol 2011, 409:189-201
17. Guo HS, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC: Active caspase 6 and caspase 6-cleaved Tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004, 165:523-531
18. Albrecht S, Bourdeau M, Bennett D, Mufson EJ, Bhattacharjee M, LeBlanc AC: Activation of caspase 6 in aging and mild cognitive impairment. Am J Pathol 2007, 170:1200-1209.
19. Klaiman G, Petzke TL, Hammond J, Leblanc AC: Targets of caspase 6 activity in human neurons and Alzheimer disease. Mol Cell Proteomics 2008, 7:1541-1555.
20. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112:389-404
21. Van der Loos CM: Multiple immunoenzyme staining: methods and visualizations for the observation with spectral imaging. J Histochem Cytochem 2008, 56:313-328.
22. Boer K, Troost D, Timmermans W, Gorter JA, Spliet WG, Nellist M, Jansen F, Aronica E: Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Neuroscience 2008,156:203-215.
23. Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, Vezzani A, Aronica E: The IL-1B system in epilepsy-associated malformations of cortical development. Neurobiol Dis 2006, 24:128-143
24. Iyer A, Zurolo E, Spliet WGM, Van Rijen PC, Baayen JC, Gorter JAEA: Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 2010, 51 (9):1763-1773
25. Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WG, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E: Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia 2009, 50:1409-1418.
26. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85
27. Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, Gomes BC, Lorenzi MV Tumor necrosis factor-a induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kB. Oncogene 2001,20:7965-7975
28. Mehler MF, Gokhan S: Developmental mechanisms in the pathogenesis of neurodegenerative diseases. Prog Neurobiol 2001, 63:337-363
29. Ben-Ari Y: Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders. Trend Neurosci 2008, 31:626-636
30. Kostovic I, Rakic P: Developmental history of the transient subplate zone in the visual and somatosensory cortex of the macaque monkey and human brain. J Comp Neurol 1990, 297:441-470.
31. Arnold SE, Trojanowski JQ: Human fetal hippocampal development: II. The neuronal cytoskeleton. J Comp Neurol 1996, 367:293-307
32. Rakic P, Lombroso PJ: Development of the cerebral cortex: I. Forming the cortical structure. J Am Acad Child Adolesc Psych 1998, 37:116-117.
33. Lazarov O, Marr RA: Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol 2010, 223:267-281
34. Lott IT, Head E: Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev 2001, 7:172-178.
35. Lockrow JP, Fortress AM, Granholm AC: Age-related neurodegeneration and memory loss in Down syndrome. Curr Gerontol Geriatr Res 2012, 2012:463909
36. Contestabile A, Benfenati F, Gasparini L: Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog Neurobiol 2010, 91:1-22.
37. de la Monte SM, Xu YY, Hutchins GM, Wands JR: Developmental patterns of neuronal thread protein gene expression in Down syndrome. J Neurol Sci 1996, 135:118-125.
38. Mattiace LA, Kress Y, Davies P, Ksiezak-Reding H, Yen SH, Dickson DW: Ubiquitin-immunoreactive dystrophic neurites in Down's syndrome brains. J Neuropathol Exp Neurol 1991, 50:547-559.
39. Abraham H, Vincze A, Veszpremi B, Kravjak A, Gomori E, Kovacs GG, Seress L: Impaired myelination of the human hippocampal formation in Down syndrome. Int J Dev Neurosci 2012, 30:147-158.
40. Popko B: Downregulating DR6 to drive remyelination. Nat Med 2011, 17:779-780.
41. Qiu CW, Sheng B, Liu J: A new therapy for the reduction of axon and neuron loss and promotion of axon and oligodendrocyte regeneration through inhibition of death receptor 6 pathway after ischemic cerebral stroke. Med Hypotheses 2012, 79:853-855.
42. Marin-Padilla M: Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study J Comp Neurol 1976,167:63-81
43. Mann DM: The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 1988, 43:99-136
44. de la Monte SM, Hedley-Whyte ET: Small cerebral hemispheres in adults with Down's syndrome: contributions of developmental arrest and lesions of Alzheimer's disease. J Neuropathol Exp Neurol 1990, 49:509-520
45. Sadowski M, Wisniewski HM, Tarnawski M, Kozlowski PB, Lach B, Wegiel J: Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology. Acta Neuropathol 1999, 97:156-164.
46. Bien J, Jefferson T, Causevic M, Jumpertz T, Muenter L, Multhaup G, Weggen S, Becker-Pauly C, Pietrzik CU: The metalloprotease meprin B generates amino terminal truncated amyloid B-peptide species. J Biol Chem 2012, 287(40)33304-33313.
47. Vella LJ, Cappai R: Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments. FASEB J 2012, 26:2930-2940.